Background The major purpose of the present study was to determine the effect of the potassium channel opener bimakalim, administered intracoronary only during the initial 10 minutes of ischemia, on myocardial infarct size in anesthetized dogs. A second aim was to test the possibility that bimakalim mediates its cardioprotective effects by accelerating the rate of myocyte action potential shortening during early ischemia. A third aim was to determine the relative potency of bimakalim
Effects of the KATP Channel Opener Bimakalim on Coronary Blood Flow, Monophasic Action Potential Duration, and Infarct Size in Dogs Zhenhai Yao, MD, PhD; Garrett J. Gross, PhD Background The major purpose of the present study was to determine the effect of the potassium channel opener bimakalim, administered intracoronary only during the initial 10 minutes of ischemia, on myocardial infarct size in anesthetized dogs. A second aim was to test the possibility that bimakalim mediates its cardioprotective effects by accelerating the rate of myocyte action potential shortening during early ischemia. A third aim was to determine the relative potency of bimakalim to open coronary vascular ATP-regulated potassium (KATP) channels versus myocyte KAT channels.
Methods and Results
Barbital-anesthetized open-chest dogs were used. In the initial studies, bimakalim (0.1 to 10 ,ug/min) was infused into the left anterior descending coronary artery (LAD), and changes in coronary blood flow and monophasic action potential duration (MAPD) were used as indexes of coronary vascular KATP channel and myocyte KATP channel activity, respectively. In subsequent infarct studies, dogs were subjected to 60 minutes of LAD occlusion followed by 4 hours of reperfusion. Based on preliminary studies, two doses of bimakalim that did not shorten MAPD during nonischemic conditions (0.1 and 0.3 ,ug/min) and one that markedly shortened MAPD during nonischemic conditions (3.0 Lg/min) or an equal volume of vehicle were infused into the LAD during the initial 10 minutes of coronary artery occlusion. Transmural myocardial blood flow was measured at 5 and 30 minutes of occlusion by the radioactive microsphere technique, and infarct size was determined at the end of 4 hours of reperfusion by triphenyltetrazolium staining. The monophasic action potential duration at 50% repolarization (MAPD5o) was measured by an epicardial probe placed in the center of the ischemic area. Bimakalim had an approximately 10-fold greater affinity for the coronary vascular than the myocardial KATP channel (ED_% coronary, -0.3 ,ug/min; ED_% myocyte, -3.0 ,ug/min). Three doses of bimakalim (0.1, 0.3, and 3.0 ,ug/min) all markedly reduced infarct size expressed as percent of the area at risk (12. 6±3.3%, 14.5+2.2%, and 14.2+5.3%, respectively, versus 27.2±5.7% in controls) to nearly equal extents. Subsequently, we found that the two higher doses of bimakalim (0.3 and 3.0 ,g/min) markedly accelerated yet the 0.1-lg/min dose of bimakalim did not significantly affect the ischemia-related shortening of the action potential during the initial 5 minutes of occlusion. In addition, 0.1 and 0.3 ,ug/min bimakalim did not increase the incidence of ventricular fibrillation during the 60 minutes of occlusion (0 of 7 and 0 of 8 dogs, respectively), whereas 3.0 ,ug/min bimakalim had a profibrillatory effect (6 of 6) compared with the control group (1 of 8). There were no significant differences between groups in systemic hemodynamics, myocardial oxygen demand, ischemic bed size, or collateral blood flow to the ischemic region.
Conclusions The results of the present study clearly reveal that a small dose (0.1 or 0.3 ,ug/min) of the KATP channel opener bimakalim administered only during the initial 10-minute period of ischemia markedly reduced myocardial infarct size to an extent equal to that of a higher profibrillatory dose in barbital-anesthetized dogs. These A left thoracotomy was performed at the fifth intercostal space, the lung was retracted, the pericardium was incised, and the heart was suspended in a cradle. A 1.0-to 1.5-cm segment of the left anterior descending coronary artery (LAD) was dissected from surrounding tissue distal to the first diagonal branch, and a calibrated electromagnetic flow probe (Statham SP 7515) was placed around the vessel. A flowmeter (Statham 2202) was used to measure coronary blood flow, and a micrometer-driven mechanical occluder was placed distal to the flow probe. The occluder was used to zero the flow probe (LAD was occluded for 10 seconds) 20 minutes before the initial coronary occlusion and later to occlude the artery. If the basal heart rate was less than 150 beats per minute, the heart was paced at that rate with rectangular pulses of 4-millisecond duration and a voltage twice threshold through bipolar electrodes sutured to the left atrial appendage. Pacing was not used in the few animals with initial rates of more than 150 beats per minute. Heart rate, hemodynamics, and LAD blood flow were monitored and recorded with a polygraph (model 7, Grass Instrument Co) throughout the experiment. The left atrial appendage was cannulated for radioactive microsphere injection. The right femoral vein was cannulated for drug administration. A small catheter with a needle (30 gauge) bent at 900 was inserted into the LAD distal to the flow probe and occluder for intracoronary drug infusions.
Chemicals
Bimakalim (EMD 52692) was generously supplied by Dr Pierre Schelling from E. Merck, Darmstadt, Germany. On the day of the experiments, 0.5 mg bimakalim was dissolved in 0.5 mL polyethylene glycol and then diluted with saline to appropriate concentrations.
Experimental Design
Animals were randomly assigned to one of four groups. In group 1, 0.3 gg/mL bimakalim solution (0.1 to 10 gg/min) was infused into the LAD at rates of 0.33 to 3.3 mL/min, and changes in coronary blood flow and MAP duration were used as indexes of coronary vascular and myocyte KATP channel activity, respectively. In four other groups, dogs were infused with either vehicle or 0.1, 0.3, or 3.0 ,ug/min bimakalim into the LAD at rates of 0.3 to 1.0 mL/min during the initial 10 minutes of occlusion to determine its effects on myocardial infarct size and MAP duration of the ischemic myocardium.
Infarct Size Determination
After 4 hours of reperfusion, the LAD was reoccluded and cannulated just distal to the occlusion site. Subsequently, 10 mL saline and 10 mL Patent blue dye were injected at equal pressures into the LAD and left atrium, respectively, to determine the anatomic area at risk (AAR) and the nonischemic area. The heart was then immediately fibrillated, removed, and sliced into serial transverse sections 6 to 7 mm in width. The nonstained ischemic area was separated from the blue-stained normal area, and the two regions were incubated at 37°C for 20 to 30 minutes in 1% 2,3,5-triphenyltetrazolium chloride (TTC) in 0.1 mol/L phosphate buffer adjusted to pH 7.4. The TTC stains the noninfarcted myocardium brick-red, indicating the presence of a formazin precipitate that results from the reduction of TTC by dehydrogenase enzymes present in viable tissue. After storage overnight in 10% formaldehyde, infarcted and noninfarcted tissues within the AAR were carefully separated and weighed. Infarct size (IS) was expressed as a percent of the AAR (IS/AAR).
Regional Myocardial Blood Flow
The radioactive microsphere technique was used to measure regional myocardial blood flow.'3 Carbonized plastic microspheres (15--gm diameter, New England Nuclear) labeled with "4'Ce, "03Ru, or 'Nb and suspended in isotonic saline with 0.01% Tween 80 added to prevent aggregation were injected into the left atrium at 5 and 30 minutes of coronary artery occlusion, as well as at the end of the 4-hour reperfusion period. At the completion of experiments, regional myocardial blood flow in the subepicardium, midmyocardium, and subendocardium of ischemic and nonischemic areas was determined.
MAP
The epicardial MAP in the ischemic region was measured by a method previously described.12"14 Before and during the first 5 minutes of ischemia, the MAP was continuously monitored.
The duration at 50% repolarization (MAPD50) was measured immediately before LAD occlusion (baseline value) and at 1, 3, and 5 minutes after the start of occlusion. Shortening of the epicardial MAPD50 was used as an index of myocardial KATP channel activity in the ischemic region.
Criteria for Exclusion
To ensure that all animals included in data analysis were healthy and exposed to a similar extent of ischemia, the following criteria were used to exclude unsatisfactory dogs: (1) subendocardial collateral flow of more than 0.15 mL*min1 *g '; (2) heart rate of more than 170 beats per minute: and (3) more than three consecutive attempts required to convert ventricular fibrillation with low-energy DC pulses applied directly to the heart.
Statistical Analysis
All values are expressed as mean±SEM. Differences between groups in hemodynamics, blood pH, myocardial collateral blood flow, and infarct size were compared using a two-factor ANOVA with repeated measures and Fisher's least significant difference test. Table 1 . Compared with the vehicletreated control group, bimakalim had no effect on heart rate, mean aortic blood pressure, left ventricular dP/dt, the rate-pressure product, and coronary blood flow at any dose throughout the experiments. Similarly, there were no differences in arterial pH or blood gases between groups (Table 2) .
Regional Myocardial Blood Flow
Regional myocardial blood flow data in the ischemic (LAD) and nonischemic (left circumflex) regions at 5 and 30 minutes after occlusion and at 4 hours of reperfusion in the four series are summarized in Table  3 . No significant differences were found between groups. (Fig 4) . Subsequently, we found that (1) intracoronary infusion with three doses of bimakalim (0.1, 0.3, or 3.0 ,ug/min) for the initial 10 minutes of occlusion markedly reduced myocardial infarct size to similar degrees; (2) the effects of the two higher doses of bimakalim in reducing infarct size were positively related to their effects in accelerating the rate of MAP shortening during the initial brief period of occlusion; (3) although the O.1-gg/min dose of bimakalim markedly reduced myocardial infarct size to a degree similar to that of the two higher doses, it did not affect ischemia-induced myocardial action potential shortening; and (4) the doses of 0.1 and 0.3 ,ug/min did not appear to have proarrhythmic effects, whereas the dose of 3.0 ,ug/min significantly increased the incidence of ventricular fibrillation during the ischemic period, although the three doses were equally efficacious in reducing infarct size.
Previous results obtained from our laboratory demonstrated that intravenous infusion of bimakalim before and throughout the occlusion period limited myocardial infarct size in canine hearts subjected to 90 minutes of coronary artery occlusion followed by reperfusion. 15 However, intravenous administration of bimakalim was found to have marked effects on systemic hemodynamics, which might be a drawback for clinical application. To avoid systemic effects, the present study was designed to determine whether brief exposure of the heart to bimakalim by intracoronary infusion only during the initial 10 minutes of ischemia was sufficient to limit myocardial infarct size.
Surprisingly, all doses (0.1, 0.3, or 3.0 pLg/min) of bimakalim administered only during the initial 10 minutes of ischemia markedly reduced infarct size to a similar extent compared with the control group. The reduction produced by the three doses of bimakalim occurred without significant effects on systemic hemody- The mechanism by which bimakalim and other potassium channel openers reduce infarct size is not fully understood. In the present study, we found that intracoronary infusion with bimakalim either at a dose of 3.0 ,g/min, which markedly shortened action potential duration, or at a dose of 0.3 ,ug/min, which had no effect 22 Thus, preventing or reducing calcium overload of the myocardium subjected to myocardial ischemia may be one important mechanism by which activation of KATP channels and a concomitant decrease in MAP duration preserve the myocardium during ischemia.
On the other hand, the findings that the 0.1-,ug/min dose of bimakalim did not significantly accelerate the ischemia-induced shortening of action potential duration yet resulted in a reduction in infarct size equal to that observed with the two higher doses clearly suggest that other factors may be involved in the cardioprotective effects of these agents and also suggest that one may be able to dissociate the electrophysiological effects of potassium channel openers from their cardioprotective properties. Recently, Quast23 reviewed data that indicate that potassium channel openers reduce the production of IP3 and calcium release from the sarcoplasmic reticulum, decrease the sensitivity of the contractile elements to calcium, and reduce calcium influx via voltage-operated calcium channels in isolated porcine coronary arteries. Whether such changes also occur in the myocardium remains to be determined but would provide some alternative mechanisms to help explain the cardioprotective effect of these compounds in the absence of enhanced action potential shortening.
KATP channel activation has been proposed by some investigators to be proarrhythmic and to increase the incidence of ventricular fibrillation.24,25 In contrast, KATP channel activation by pinacidil has also been reported to be antiarrhythmic.26 These conflicting results may be attributable to differences in the type of arrhythmias investigated, the conditions in which they occur, and species differences. The present results showed that 3.0 .g/min bimakalim significantly increased the incidence of ventricular fibrillation, whereas 0.1 or 0.3 ,ug/min bimakalim did not appear to have profibrillatory effects. Therefore, a 30-fold lower dose of bimakalim, which may lead to local concentrations during intracoronary infusion corresponding to those obtained in plasma after the intravenous application of bimakalim in therapeutic doses, was equipotent with the high, probably toxic dose in reducing infarct size but showed no arrhythmogenic tendency and no shortening of the action potential. These results indicate that therapeutic doses of bimakalim or perhaps other KATP channel openers may be potential candidates for clinical trials, possibly on patients subjected to short periods of ischemia such as angioplasty.
In conclusion, the results of the present study clearly reveal that bimakalim administered only briefly during the initial period of ischemia markedly reduces myocardial infarct size in barbital-anesthetized dogs and suggest that bimakalim and other potassium channel openers may at least partially exert their cardioprotective effects in reducing infarct size by accelerating KATP channel activation and the rate of ischemic myocyte action potential shortening. That the lowest dose of bimakalim reduced infarct size to a similar extent as two higher doses without accelerating the shortening of the action potential suggests that other mechanisms may also be involved in the cardioprotective actions of potassium channel openers. Because low doses of bimakalim reduced infarct size in the absence of proarrhythmic effects, brief exposure of the ischemic myocardium to a small dose of a potassium channel opener such as bimakalim may be a useful new approach for the treatment of certain clinical situations where acute myocardial ischemia is present.
